Jim Shannon – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Jim Shannon on 2016-01-12.

To ask the Secretary of State for Health, how many patients are receiving nivolumab for locally advanced or metastatic squamous non-small cell lung cancer in (a) England and (b) Strangford; and when NICE plans to complete its appraisal of that drug.

George Freeman

NHS England has advised that it understands that the manufacturer of nivolumab (Opdivo), Bristol-Myers Squibb, received 73 registrations for nivolumab for locally advanced or metastatic squamous non-small cell lung cancer through the Early Access to Medicines Scheme before the scientific opinion expired in July 2015. A geographical breakdown of this figure is not available.

NHS England does not currently fund nivolumab for metastatic squamous non-small cell lung cancer and has advised that its funding position will be determined by the National Institute for Health and Care Excellence’s final technology appraisal guidance which is expected in May 2016. Further information is available at:

www.nice.org.uk/guidance/indevelopment/gid-tag506

“